- Home
- ODP vs MREO Comparison
ODP vs MREO Comparison
Compare ODP & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODP
- MREO
- Stock Information
- Founded
- ODP 1986
- MREO 2015
- Country
- ODP United States
- MREO United Kingdom
- Employees
- ODP N/A
- MREO N/A
- Industry
- ODP Other Specialty Stores
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- ODP Consumer Discretionary
- MREO Health Care
- Exchange
- ODP Nasdaq
- MREO Nasdaq
- Market Cap
- ODP 419.0M
- MREO 424.5M
- IPO Year
- ODP N/A
- MREO N/A
- Fundamental
- Price
- ODP $16.69
- MREO $2.85
- Analyst Decision
- ODP Hold
- MREO Strong Buy
- Analyst Count
- ODP 1
- MREO 7
- Target Price
- ODP $28.00
- MREO $7.71
- AVG Volume (30 Days)
- ODP 457.8K
- MREO 1.2M
- Earning Date
- ODP 08-06-2025
- MREO 08-12-2025
- Dividend Yield
- ODP N/A
- MREO N/A
- EPS Growth
- ODP N/A
- MREO N/A
- EPS
- ODP N/A
- MREO N/A
- Revenue
- ODP $6,820,000,000.00
- MREO N/A
- Revenue This Year
- ODP N/A
- MREO N/A
- Revenue Next Year
- ODP N/A
- MREO $54.07
- P/E Ratio
- ODP $11.70
- MREO N/A
- Revenue Growth
- ODP N/A
- MREO N/A
- 52 Week Low
- ODP $11.85
- MREO $1.58
- 52 Week High
- ODP $43.31
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- ODP 47.89
- MREO 64.74
- Support Level
- ODP $16.32
- MREO $2.61
- Resistance Level
- ODP $18.77
- MREO $2.85
- Average True Range (ATR)
- ODP 0.81
- MREO 0.17
- MACD
- ODP -0.23
- MREO 0.03
- Stochastic Oscillator
- ODP 22.68
- MREO 88.83
About ODP The ODP Corporation
The ODP Corp operates an integrated B2B distribution platform with divisions focusing on various sectors: ODP Business Solutions serves small to enterprise-level companies with office supplies, technology, furniture, and services. Office Depot Division caters to retail consumers and small businesses through retail locations and eCommerce platforms, offering office supplies, technology, and business services. Veyer Division specializes in supply chain, distribution, and procurement services for both internal and third-party customers, with a focus on global operations. Varis Division offers a tech-enabled B2B indirect procurement marketplace, providing a seamless buying experience and advanced spend management tools. Revenue primarily stems from the Veyer division.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).